Strategic Collaborations Sernova's Cell Pouch Bio-hybrid Organ targets type 1 diabetes and other chronic diseases, creating potential co-development or licensing opportunities with large pharma and regenerative medicine players. The company can leverage diabetes care networks and transplant centers to initiate partnerships, aided by credible leadership and recent financing momentum.

Financing Momentum Recent financings strengthen the balance sheet and reduce financing overhang, signaling a ready posture for deal-making and milestone-driven partnerships. This creates an opening for strategic investors or partners to fund trials and share downstream value through revenue or milestone arrangements.

Leadership Credibility The appointment of John L. Brooks III as Chair brings deep T1D expertise and venture-building experience, enhancing board-level credibility with researchers and potential partners. His background can accelerate academic collaborations and industry introductions crucial for advancing regenerative medicine programs.

North American Pathways Headquartered in Canada with active activity in North America, Sernova presents opportunities to engage with US regulators, CROs, and CMOs for trial execution and scalable manufacturing. BD conversations can focus on regulatory strategy, cross-border trial partnerships, and co-development deals with North American partners.

Market Expansion While focused on T1D, the Cell Pouch technology has potential indications beyond diabetes, widening the addressable market for partnerships and licensing. This supports multi-indication deals with staged milestones and risk-sharing structures with regenerative medicine and clinical research organizations.